This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 11 pp 11025—11041
LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis
Figure 6. LncRNA ADAMTS9-AS2 regulated NLRP3 inflammasome in GC cells by sponging miR-223-3p. (A) The targeting sites of miR-223-3p and NLRP3 mRNA were predicted by the online starBase software (http://hopper.si.edu/wiki/mmti/Starbase). Dual-luciferase reporter gene system was employed to validate the binding sites of miR-223-3p and NLRP3 mRNA in (B) SGC7901 cells and (C) BGC-823 cells. (D) RIP assay was used to evaluate the binding ability of miR-223-3p and 3’ UTR regions of NLRP3 mRNA. (E–H) Western Blot was performed to detect the expression levels of NLRP3 in SGC7901 and BGC-823 cells. (“Mic” represented “miR-223-3p mimic” and “Inhi” represented “miR-223-3p inhibitor”). Each experiment repeated at least 3 times. “NS” represented “no statistical significance”, *P < 0.05, **P < 0.01.